Patients & Caregivers

Patients play a key role in clinical trials to find new cancer treatments. Learn about our current clinical trials to see if you or your loved one may be able to join.

#PatientsAreWaiting

At Kinnate, we are driven by the urgency and knowledge that patients are waiting for new, effective cancer medicines. 

We’re focused on developing targeted treatments for people with cancers that have certain genetic mutations (changes in genes that cause cancer to grow), and:

  1. There are no currently approved targeted therapies for the genetic mutation in their cancer
  2. Approved targeted therapies did not work or stopped working to treat their cancer 

Find a Kinnate clinical trial to join

Read below about our current clinical trials. If you have questions or want to join a clinical trial, please email us.

Our current clinical trials

A clinical trial of the drug KIN-2787 in adults with BRAF-positive cancers and NRAS-positive melanoma

KN-8701 is a multi-center, open-label, two-part trial that will have about 155 patients. The main goals of this trial are to learn about the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with Class I, Class II, or Class III BRAF-mutated advanced or metastatic solid tumors, and NRAS-mutated melanoma.

The dose-escalation portion (Part A) of the trial will determine the recommended dose and schedule of KIN-2787 for further evaluation in patients with BRAF-mutated solid tumors or NRAS-mutated melanoma. In Part A1, KIN-2787 will be administered as a single agent. In Part A2, KIN-2787 will be administered in combination with binimetinib, a mitogen-activated protein kinase (MEK) inhibitor.

The dose-expansion phase (Part B) will assess the safety and efficacy of KIN-2787 at the recommended dose and schedule in patients with cancers that contain BRAF Class II or III mutations, including lung cancer, melanoma, and other selected solid tumors.

Visit this trial’s website here to learn more.

A clinical trial of the drug KIN-3248 in adults with FGFR-positive cancers

KN-4802 is a multi-center, open-label, two-part trial of approximately 120 participants. The main goals of this trial are to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248 in adults with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations.

The dose-escalation portion (Part A) of the trial will determine the maximum tolerated dose (MTD) of KIN-3248 in patients with FGFR2 and/or FGFR3 gene alterations.

The dose-expansion phase (Part B) may open once either the MTD and/or a biologically active dose of KIN-3248 is identified. Part B is aimed at evaluating the safety and efficacy of KIN-3248 at the recommended dose and schedule in participants with cancers harboring FGFR2 and/or FGFR3 gene alterations, including intrahepatic cholangiocarcinoma (ICC), urothelial cancer (UC), and other solid tumors.

Each and every participant in our clinical studies plays an essential role in support of our mission to advance precision cancer medicines, and we are deeply grateful for their participation.

Richard Williams, MBBS, PhD
Chief Medical Officer, Kinnate

For questions about our clinical trials, contact our team. 

Every cancer has a weak spot. We design therapies that take advantage of them.